Human monocytes in culture synthesize and secrete lipoprotein lipase. 1982

P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown

UI MeSH Term Description Entries
D008071 Lipoprotein Lipase An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. The enzyme hydrolyzes triacylglycerols in chylomicrons, very-low-density lipoproteins, low-density lipoproteins, and diacylglycerols. It occurs on capillary endothelial surfaces, especially in mammary, muscle, and adipose tissue. Genetic deficiency of the enzyme causes familial hyperlipoproteinemia Type I. (Dorland, 27th ed) EC 3.1.1.34. Heparin-Clearing Factor,Lipemia-Clearing Factor,Diacylglycerol Lipase,Diglyceride Lipase,Post-Heparin Lipase,Postheparin Lipase,Postheparin Lipoprotein Lipase,Factor, Heparin-Clearing,Factor, Lipemia-Clearing,Heparin Clearing Factor,Lipase, Diacylglycerol,Lipase, Diglyceride,Lipase, Lipoprotein,Lipase, Post-Heparin,Lipase, Postheparin,Lipase, Postheparin Lipoprotein,Lipemia Clearing Factor,Lipoprotein Lipase, Postheparin,Post Heparin Lipase
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D001053 Apolipoproteins Protein components on the surface of LIPOPROTEINS. They form a layer surrounding the hydrophobic lipid core. There are several classes of apolipoproteins with each playing a different role in lipid transport and LIPID METABOLISM. These proteins are synthesized mainly in the LIVER and the INTESTINES. Apolipoprotein
D001056 Apolipoproteins C A group of apolipoproteins that can readily exchange among the various classes of lipoproteins (HDL; VLDL; CHYLOMICRONS). After lipolysis of TRIGLYCERIDES on VLDL and chylomicrons, Apo-C proteins are normally transferred to HDL. The subtypes can modulate remnant binding to receptors, LECITHIN CHOLESTEROL ACYLTRANSFERASE, or LIPOPROTEIN LIPASE. Apo-C,Apo C,ApoC,Apoprotein (C),Apoproteins C
D012965 Sodium Chloride A ubiquitous sodium salt that is commonly used to season food. Sodium Chloride, (22)Na,Sodium Chloride, (24)NaCl
D053304 Apolipoprotein C-II A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS. It contains a cofactor for LIPOPROTEIN LIPASE and activates several triacylglycerol lipases. The association of Apo C-II with plasma CHYLOMICRONS; VLDL, and HIGH-DENSITY LIPOPROTEINS is reversible and changes rapidly as a function of triglyceride metabolism. Clinically, Apo C-II deficiency is similar to lipoprotein lipase deficiency (HYPERLIPOPROTEINEMIA TYPE I) and is therefore called hyperlipoproteinemia type IB. Apo C-II,ApoC2,Apolipoprotein C-2,Apolipoprotein CII,Apoprotein C-II,Apo C II,Apolipoprotein C 2,Apolipoprotein C II,Apoprotein C II
D053305 Apolipoprotein C-III A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2). Apo C-III,Apo C-III-2,ApoC-III,Apolipoprotein C-III-0,Apolipoprotein C-III-1,Apolipoprotein CIII,Sialyl Apo C-III,Sialyl Apolipoprotein C-III,Apo C III,Apo C III 2,Apo C-III, Sialyl,ApoC III,Apolipoprotein C III,Apolipoprotein C III 0,Apolipoprotein C III 1,Apolipoprotein C-III, Sialyl,Sialyl Apo C III,Sialyl Apolipoprotein C III

Related Publications

P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
June 1977, The Journal of experimental medicine,
P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
November 1988, Scandinavian journal of clinical and laboratory investigation,
P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
January 1985, Blood,
P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
March 1982, Proceedings of the National Academy of Sciences of the United States of America,
P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
January 1985, Biochemical and biophysical research communications,
P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
December 1984, Nihon Ika Daigaku zasshi,
P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
April 1992, Biochemical and biophysical research communications,
P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
January 1984, European journal of cell biology,
P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
December 1992, Experimental cell research,
P Wang-Iverson, and A Ungar, and J Bliumis, and P R Bukberg, and J C Gibson, and W V Brown
July 1993, The Journal of investigative dermatology,
Copied contents to your clipboard!